DEveloping Tests for Endometrial Cancer deTection (DETECT): protocol for a diagnostic accuracy study of urine and vaginal samples for the detection of endometrial cancer by cytology in women with postmenopausal bleeding. by Jones, Eleanor R et al.
1Jones ER, et al. BMJ Open 2021;11:e050755. doi:10.1136/bmjopen-2021-050755
Open access 
DEveloping Tests for Endometrial 
Cancer deTection (DETECT): protocol 
for a diagnostic accuracy study of urine 
and vaginal samples for the detection of 
endometrial cancer by cytology in 
women with postmenopausal bleeding
Eleanor R Jones,1,2 Suzanne Carter,1 Helena O'Flynn,1 Kelechi Njoku,1 
Chloe E Barr,1,2 Nadira Narine,3 David Shelton,3 Durgesh Rana,3 
Emma J Crosbie   1,2
To cite: Jones ER, Carter S, 
O'Flynn H, et al.  DEveloping 
Tests for Endometrial Cancer 
deTection (DETECT): protocol 
for a diagnostic accuracy 
study of urine and vaginal 
samples for the detection of 
endometrial cancer by cytology 
in women with postmenopausal 
bleeding. BMJ Open 
2021;11:e050755. doi:10.1136/
bmjopen-2021-050755
 ► Prepublication history and 
additional supplemental material 
for this paper are available 
online. To view these files, 
please visit the journal online 
(http:// dx. doi. org/ 10. 1136/ 
bmjopen- 2021- 050755).
Received 27 February 2021
Accepted 05 July 2021
For numbered affiliations see 
end of article.
Correspondence to
Professor Emma J Crosbie;  
 emma. crosbie@ manchester. 
ac. uk
Protocol
© Author(s) (or their 
employer(s)) 2021. Re- use 
permitted under CC BY. 
Published by BMJ.
ABSTRACT
Introduction Postmenopausal bleeding (PMB), the 
red flag symptom for endometrial cancer, triggers 
urgent investigation by transvaginal ultrasound scan, 
hysteroscopy and/or endometrial biopsy. These 
investigations are costly, invasive and often painful or 
distressing for women. In a pilot study, we found that 
voided urine and non- invasive vaginal samples from 
women with endometrial cancer contain malignant 
cells that can be identified by cytology. The aim of the 
DEveloping Tests for Endometrial Cancer deTection 
(DETECT) Study is to determine the diagnostic test 
accuracy of urine and vaginal cytology for endometrial 
cancer detection in women with PMB.
Methods and analysis This is a multicentre diagnostic 
accuracy study of women referred to secondary care 
with PMB. Eligible women will be asked to provide a 
self- collected voided urine sample and a vaginal sample 
collected with a Delphi screener before routine clinical 
procedures. Pairs of specialist cytologists, blinded to 
participant cancer status, will assess and classify samples 
independently, with differences settled by consensus 
review or involving a third cytologist. Results will be 
compared with clinical outcomes from standard diagnostic 
tests. A sample size of 2000 women will have 80% power 
to establish a sensitivity of vaginal samples for endometrial 
cancer detection by cytology of ≥85%±7%, assuming 5% 
endometrial cancer prevalence. The primary objective is to 
determine the diagnostic accuracy of urogenital samples 
for endometrial cancer detection by cytology. Secondary 
objectives include the acceptability of urine and vaginal 
sampling to women.
Ethics and dissemination This study has been approved 
by the North West–Greater Manchester West Research 
Ethics Committee (16/NW/0660) and the Health Research 
Authority. Results will be disseminated through publication 
in peer- reviewed scientific journals, presentation at 
conferences and via charity websites.
Trial registration number ISRCTN58863784.
INTRODUCTION
In the UK, over 9000 women are diagnosed 
with endometrial cancer every year.1 The 
red flag symptom for endometrial cancer is 
postmenopausal bleeding (PMB).2 A woman 
with PMB is referred by her general practi-
tioner (GP) on the urgent ‘suspected cancer’ 
pathway to a rapid access gynaecology clinic, 
where she is offered a series of invasive, 
unpleasant and often painful tests to rule out 
endometrial cancer.3 These include transvag-
inal sonography (TVS), outpatient hysteros-
copy and endometrial biopsy.4 Together, these 
tests cost the National Health Service (NHS) 
around £750/woman.5 PMB is extremely 
common, and only 5%–10% of women with 
PMB are ultimately diagnosed with endome-
trial cancer.6 7 Indeed, it has been estimated 
that 5% of all GP referrals to gynaecology, as 
Strengths and limitations of this study
 ► This is a prospective evaluation of a novel, non- 
invasive endometrial cancer detection tool that 
could transform diagnostic pathways for women 
with postmenopausal bleeding (PMB).
 ► Samples will be taken prior to routine clinical proce-
dures to avoid inadvertent contamination of samples 
by iatrogenically dislodged endometrial cells.
 ► Cytologists are blinded to participant cancer status 
until they provide their consensus report.
 ► Passive follow- up of participants will ensure missed 
cancer diagnoses are minimised.
 ► Recruitment is limited to women with PMB, and 
results may not be applicable to premenopausal 
women or those with atypical presentations of en-
dometrial cancer.
2 Jones ER, et al. BMJ Open 2021;11:e050755. doi:10.1136/bmjopen-2021-050755
Open access 
many as 150 000 women per year in the UK alone, relate 
to PMB.5 A simple, non- invasive test deployed in primary 
care to target those at risk of endometrial cancer for 
invasive testing, while safely reassuring the vast majority 
of healthy women, could transform diagnostic pathways 
for endometrial cancer. In the UK, it would save thou-
sands of women every year from the psychological and 
physical sequelae of invasive tests and create substantial 
cost savings for the NHS (potential saving in excess of 
£100 million/year).
The development of novel non- invasive detection 
tools was voted the most important research priority for 
detecting cancer early in the recently completed James 
Lind Alliance Priority Setting Partnership.8 In endo-
metrial cancer, the anatomical continuity between the 
uterus and the lower genital tract facilitates the collec-
tion of shed tumour cells using non- invasive sampling 
methodologies.9–13 We found that shed tumour cells can 
be collected from the vagina by gentle lavage using the 
Delphi screener and from voided urine samples, which 
are inevitably contaminated by endometrial debris in 
women with uterine bleeding.14 These cells can be distin-
guished from normal squamous, urothelial and glandular 
cells of the urogenital tract by cytology, although certain 
benign mimics (eg, polyps and atrophy) can cause difficul-
ties with interpretation. In our pilot study of 113 women 
with unexplained PMB, urine and/or vaginal cytology 
showed 100% sensitivity and 100% negative predictive 
value (NPV) for endometrial cancer detection; it iden-
tified all seven cancers (four endometrial, one cervical, 
one ovarian and one bladder) for a 11% false positive 
rate. Furthermore, mean pain scores were significantly 
lower for vaginal sampling (1.61, SD 2.04) than for diag-
nostic hysteroscopy (4.28, SD 2.61, p<0.001) and endo-
metrial biopsy (4.88, SD 3.49, p<0.001), respectively.14 
Thus, urogenital cytology has considerable potential as 
a well- tolerated ‘rule out’ test to enable quick reassur-
ance for most women who present to primary care with 
PMB and urgent referral for those who test positive. To 
confirm its clinical utility for endometrial cancer detec-
tion, urine and vaginal cytology must now be tested in a 
large prospective study of women undergoing investiga-
tion for PMB. The aim of the DEveloping Tests for Endo-
metrial Cancer deTection (DETECT) Study is to estimate 
the diagnostic accuracy of urine and vaginal samples for 
endometrial cancer detection by cytology in women with 
PMB.
METHODS
This protocol is reported in accordance with Standards 
for Reporting of Diagnostic Accuracy Studies (STARD) 
guidelines.15
Study design
DETECT is a prospective multicentre diagnostic accuracy 
study of urine and vaginal cytology for endometrial cancer 
detection in women with PMB (study schema, figure 1).
Participants and recruitment
Consecutive women will be recruited from gynaecology 
clinics at seven hospital sites across the North West 
England: St Mary’s Hospital, Trafford General Hospital, 
Wythenshawe Hospital, Royal Oldham Hospital, North 
Manchester General Hospital, Fairfield General Hospital 
and Tameside Hospital.
Inclusion criteria
1. Women who have been referred to secondary care for 
investigation of PMB.
2. Written, informed consent to participate.
Exclusion criteria
1. Abnormal bleeding before the menopause.
2. Previous treatment for endometrial cancer.
3. Previous hysterectomy.
4. Mirena coil in situ or removed within the last 3 months.
Figure 1 Study schema illustrating the flow of participants 
through the study, interventions and evaluations. DETECT, 
DEveloping Tests for Endometrial Cancer deTection; PMB, 
postmenopausal bleeding.
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5. Any other condition that would compromise partici-
pant safety or data integrity.
PMB will be defined as vaginal bleeding that occurs 
more than 12 months after menstruation has stopped due 
to menopause.
Participant withdrawal
Participants may withdraw from the study at their own 
request or at the discretion of the investigator. With-
drawal from the study will not affect patient care.
Sample size
With a sample size of ~2000 women and an endometrial 
cancer prevalence of 5%,5 there will be approximately 
1900 women without endometrial cancer and 100 women 
with endometrial cancer. The study will have 80% power 
to determine the sensitivity of the test at ≥85%±7% and 
the specificity of the test at ≥85%±2%. At 85% specificity, 
around 1630 women will have a negative test result, giving 
the test a NPV) of 99.1% (98.5% and 99.4%). These esti-
mates originate from the pilot study, where sensitivity and 
specificity were both >85%. The prevalence of endome-
trial cancer will determine the final sample size. If the 
prevalence of endometrial cancer is greater than 5%, 
fewer than 2000 women will be needed; if it is less than 
5%, more women will be needed to determine the sensi-
tivity of the test at ≥85%±7%.
Study duration
In the pilot study, 90% of eligible women agreed to 
participate. Women will be recruited between September 
2018 and September 2021 with clinical outcome data 
collected until March 2022. To achieve the recruitment 
target of ~2000 women, approximately 20 women will be 
recruited per week across the seven hospital sites. A tempo-
rary pause on recruitment to the study was initiated in 
March 2020 because of the COVID-19 pandemic. Recruit-
ment recommenced in June 2020 but with COVID-19 
restrictions in place, meaning that recruitment rate is 
slower than pre- pandemic (approximately 10 women per 
week across recruitment sites).
Invitational procedure
Eligible women will be identified from referral letters 
and clinic lists by hospital clinical staff. A letter inviting 
participation and a detailed participant information 
sheet (PIS) will be sent by post to their home address. 
Potential participants will have the opportunity to discuss 
the study over the telephone with members of the study 
research team prior to their appointment. Due to the 
urgent nature of referrals, some women are offered short- 
notice clinical appointments by telephone. Where there 
is insufficient time for invitational material to be received 
by post, women will be informed about the study via tele-
phone and/or invited to participate on arrival at the 
clinic. Women will be invited to read the PIS and ask ques-
tions about the study before providing written, informed 
consent to participate.
Baseline clinical data
The following demographical and baseline clinical data 
will be obtained: age, ethnicity, socioeconomic status, 
education level, body mass index (BMI), smoking status, 
parity, age of menopause, use of contraceptives, hormone 
replacement therapy or tamoxifen, history of hyperten-
sion, hypercholesterolaemia, diabetes mellitus, polycystic 
ovary syndrome, thyroid disease, coagulopathy, Lynch 
syndrome, cervical screening history, endometrial hyper-
plasia and personal or family history of cancer. Women 
will be asked in detail about their help- seeking behaviour 
and the onset, duration and extent of their PMB.
Index tests
The timing of urine and vaginal sampling is important to 
ensure validity of the results. Both research samples will 
be taken before any routine clinical procedures to avoid 
inadvertent contamination with iatrogenically dislodged 
endometrial cells (study schema, figure 1). Of the two 
research samples, urine will be collected first because 
vaginal sampling will remove naturally shed uterine 
debris from the lower genital tract and affect interpreta-
tion of the results.
Urine samples
Using both written and verbal instructions, we will ask 
women to bring to clinic a first catch sample of their first 
urinary void of the day, collected in a sterile pot. A second 
voided urine sample will be collected by the participant 
on arrival at the clinic, before any other research or clin-
ical procedures are carried out. This will ensure that every 
woman has at least one satisfactory urine sample available 
for analysis.
Vaginal sample
The vaginal sample will be taken by the research practi-
tioner using a Delphi screener (Rovers Medical Devices, 
Oss, the Netherlands)16 according to the following 
protocol, with the participant in the supine position, 
knees bent and legs apart. The Delphi screener is inserted 
into the posterior fornix of the vagina and 3 mL saline 
expelled from its reservoir by depressing the plunger for 
3 s. The sample is then collected by suction following 
release of the plunger while slowly rotating and with-
drawing the device. A dry pot at the introitus collects any 
residual fluid. Additional samples are obtained by refilling 
the reservoir with saline and repeating the steps above 
until clear fluid is obtained (maximum of three times).
Sample handling
Urine samples will be tested for haematuria by dipstick. 
Urine and vaginal samples will be fixed with equal volumes 
of BD CytoRich Red Preservative (Becton, Dickinson and 
Company, the USA) to preserve cellular integrity, prevent 
degradation and inhibit bacterial overgrowth. Samples 
will be sent to the Manchester Cytology Centre at the 
Manchester University NHS Foundation Trust (MFT). 
Samples will be anonymised and labelled with sample 
type (urine or vaginal fluid) and a unique study identifier 
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(study ID) to prevent accidental unblinding of the cytopa-
thology team. With the exception of whether the partic-
ipant is taking exogenous hormones, all clinical data 
will be withheld from the cytology team until consensus 
results are received. Second urine samples will be fixed 
with BD CytoRich Red Preservative and stored at 4°C until 
the first urine sample has undergone cytological assess-
ment. This second sample will undergo cytological review 
if the first urine sample is inadequate for analysis or post 
hoc, if the first urine sample is false negative for endome-
trial cancer detection. Residual samples will be stored in 
the MFT Biobank for future biomarker discovery work. 
Samples will be either embedded in agar cell blocks to 
preserve cellular integrity for future immunocytochem-
istry or centrifuged to pellet the cellular material. The 
resulting pellet plus aliquots of the supernatant will be 
stored at −80°C.
Cytological assessment
Samples will be centrifuged at 3000 revolutions per 
minute (RPM) for 5 min, supernatant decanted and the 
pellet resuspended in 6 mL BD CytoRich Red Preserva-
tive. After 1 hour, the fixed sample will be centrifuged 
at 1500 RPM for 10 min, supernatant decanted and the 
remaining pellet prepared into a liquid- based cytology 
Papanicolaou stained slide using the BD PrepStain 
(Becton Dickinson UK) according to the manufactur-
er’s instructions. The stained slide will be dehydrated in 
two changes of industrial methylated spirits, cleared in 
two changes of xylene and cover- slipped. Two observers, 
a consultant cytopathologist and a consultant biomed-
ical scientist, will review each slide independently and 
record their results. A second consultant cytopathologist 
will review any discrepant cases, which will be settled by 
consensus review at a multiheaded microscope. Final 
cytology results will be logged under the unique study ID 
on the study database. intraobserver and interobserver 
variability will be determined by blinded, independent 
review of a random selection of anonymised test positive, 
test negative, complex and discrepant cases at the end of 
the study and reported separately.
Classification of cytology results
Cytology slides will be reported according to the classifi-
cation system shown in table 1. For the primary analysis, 
atypical cells of uncertain significance (ACUS), suspi-
cious, adenocarcinoma or malignant (other) cytology 
results will be considered positive. Glandular cells and no 
malignant cells seen will be considered negative. Unsat-
isfactory results will not be classified as either positive or 
negative, and the participant will be invited to provide a 
second sample for cytological analysis. Secondary analysis 
will include cancers of other pelvic sites (cervix, vagina, 
uterus, ovary, fallopian tube, bladder,kidney or bowel). 
Sensitivity analysis will consider the diagnostic perfor-
mance of positive urogenital cytology that includes glan-
dular results as potentially malignant findings.
Clinical diagnostic pathway
Women will be investigated by TVS, outpatient hysteros-
copy and/or endometrial biopsy according to local clin-
ical diagnostic pathways for the investigation of PMB 
(figure 2).3 All women will have their endometrium 
measured by TVS. Those with an endometrial thick-
ness <4 mm will be considered at low risk of endome-
trial cancer and alternative diagnoses explored. Women 
with ≥4 mm endometrial thickness will undergo an endo-
metrial biopsy using a pipelle endometrial sampler. Those 
with an irregular thickened endometrium, where focal 
pathology is visualised or suspected, will have an outpatient 
hysteroscopy and suspicious lesions biopsied under direct 
vision. Hysteroscopy will be performed under general 
anaesthesia where outpatient hysteroscopy fails, biopsies 
are inadequate for diagnostic purposes or uterine instru-
mentation is poorly tolerated. Endometrial polyps will be 
resected to allow full histological interpretation. Tissue 
samples will be formalin- fixed, paraffin- embedded, cut 
into 4 µm sections, stained with H&E and cover- slipped as 
per routine practice. At least one pathologist will review 
all biopsies; suspicious or abnormal biopsies will be 
reviewed by two specialist gynaecological pathologists at 
the cancer centre (St Mary’s Hospital) as per routine clin-
ical practice; difficult cases will be reviewed by additional 
specialist members of the gynaecological pathology team. 
Hysterectomy specimens will be fixed, cut, sectioned and 
Table 1 Cytological classification
Cytology result Cytological findings Primary analysis Sensitivity analysis
Unsatisfactory* Sample obscured by debris, lymphocytes or bacteria Indeterminate Indeterminate
NMCS No malignant cells seen Negative Negative
Glandular cells Endometrial glandular cells seen Negative Positive
ACUS Atypical cells of uncertain significance Positive Positive
Suspicious Atypical glandular cells, suspicious for malignancy Positive Positive
Adenocarcinoma Adenocarcinoma malignant cells seen Positive Positive
Malignant (others) Malignant cells of non- endometrial origin Positive Positive
*Urine according to the Paris criteria.
5Jones ER, et al. BMJ Open 2021;11:e050755. doi:10.1136/bmjopen-2021-050755
Open access
reviewed according to the International Federation of 
Gynecology and Obstetrics (FIGO) 2009 staging criteria 
(endometrial cancer) and the WHO classification system 
(atypical hyperplasia).17 18
Reference standard
The reference standard is histology where endometrial 
tissue is collected for routine diagnostic and staging 
purposes. The hysterectomy specimen will be used in pref-
erence to the endometrial biopsy, where available within 
3 months of endometrial biopsy and where there was no 
treatment with neoadjuvant chemotherapy or hormone 
therapy. Histology results will be classified as inadequate, 
benign, atypical hyperplasia and endometrial cancer (of 
any histological subtype or grade). For the primary anal-
ysis, a histological diagnosis of endometrial cancer will be 
considered a positive result. We will report overall results 
as well as a breakdown by histological subtype and stage 
of disease. Hyperplasia and benign endometrium will 
be considered a negative result. In secondary analyses, 
cancers of other pelvic sites (cervix, vagina, uterus, ovary, 
fallopian tube, bladder, kidney or bowel) will be consid-
ered a positive result. We will record cases of atypical 
hyperplasia and their cytological interpretation. In cases 
where an endometrial biopsy is not indicated (endome-
trial thickness <4 mm and/or normal hysteroscopy) or 
fails (inadequate sample), the reference standard will 
be discharge from diagnostic workup. Passive clinical 
follow- up of negative women will ensure missed diagnoses 
of endometrial cancer are minimised. This will involve 
monitoring for any subsequent rereferrals to our service. 
A diagnosis of endometrial cancer within 3 months of 
initial discharge from diagnostic workup will be consid-
ered a positive clinical result.
Blinding
In most cases, research samples will be collected prior 
to routine diagnostic workup, and sample takers will be 
blinded to participant cancer outcomes. If the propor-
tion of cases is less than 5% at the midpoint of the study, 
the cohort will be enriched with endometrial cancer 
diagnoses by recruiting higher- risk women (endometrial 
thickness >4 mm on TVS) and those with proven endo-
metrial cancer prior to hysterectomy. Care will be taken 
to collect research samples at least 7 days after any diag-
nostic uterine instrumentation. The cytology team will 
always be blinded to the cancer status of participants 
when performing cytological review of urine and vaginal 
samples. They will have no access to clinical data or results 
of routine diagnostic tests. Individual participants will not 
routinely receive their cytology results.
Outcome measures
Primary outcome measure
Sensitivity—the proportion of women with endometrial 
cancer who test positive by cytology (true positive rate) 
and specificity—the proportion of women who do not have 
endometrial cancer who test negative by cytology (true 
negative rate). The accuracy of cytology (index test) will 
be defined by the results of standard endometrial cancer 
diagnostic tests (reference standard, figure 2).
Secondary outcome measures
1. NPV—the proportion of women with a negative test 
who do not have endometrial cancer and positive pre-
dictive value—the proportion of women with a positive 
test who have endometrial cancer.
2. False positive/negative rates (and clinical scenarios as-
sociated with these).
3. Overall diagnostic accuracy of cytology for endometri-
al cancer detection.
4. Clinical performance of cytology for the detection of 
endometrial, cervical or bladder cancer.
5. Clinical performance of cytology for the detection of 
any pelvic cancer.
6. Test acceptability (short questionnaire to compare 
acceptability of urogenital sampling with standard 
diagnostic tests in a proportion of participants, eg, 
5%–10%).
Vaginal or urine cytology
1. Sensitivity and specificity of vaginal or urine cytology 
alone for endometrial cancer detection.
2. NPV, positive predictive value and false positive/nega-
tive rates of vaginal or urine cytology alone for endo-
metrial cancer detection.
3. Overall diagnostic accuracy of vaginal or urine cytolo-
gy alone for endometrial cancer detection.
4. Clinical performance of vaginal or urine cytology 
alone for the detection of endometrial, cervical or 
bladder cancer.
Figure 2 Diagnostic pathway for women referred to 
secondary care for the urgent investigation of unexplained 
postmenopausal bleeding (PMB).
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5. Clinical performance of vaginal or urine cytology 
alone for the detection of any pelvic cancer.
Handling of discordant results
The accuracy of urogenital cytology will be measured 
against standard diagnostic tests for endometrial cancer. 
Concordance of cytology results between observers will 
be recorded, but primary analysis will consider ‘ACUS’, 
‘suspicious’, ‘adenocarcinoma’ or ‘malignant (others)’ 
cytology results by consensus opinion to be a positive 
result. ‘False negative’ results, where standard tests iden-
tify endometrial cancer but urogenital cytology does not, 
will be reviewed to identify possible contributing factors 
(patient factors, tumour factors or test errors). Subject 
to ongoing consent, women will be resampled before 
they undergo hysterectomy, to determine whether repeat 
sampling is helpful for missed cases. This will be possible 
because cytology results will be reported prospectively, 
in ‘real time’ and on a weekly basis, wherever possible. 
Cytology review of missed cases will be carried out at a 
multiheaded microscope by the cytology team. Second±-
further slides will be prepared and reviewed where suffi-
cient residual sample allows. ‘False positive’ cases, where 
urogenital cytology is positive but standard tests are 
not, will be handled carefully. If the diagnostic pathway 
(figure 2) has not been completed, the responsible clini-
cian will be contacted and asked to consider further tests, 
for example, hysteroscopy or an MRI scan. If the malig-
nant cells identified by cytology could have originated 
elsewhere, further tests may be warranted (eg, cystoscopy 
and colposcopy). Retrospective blinded review of 10% 
of cases, including test positive, test negative, complex 
and discrepant cases, will facilitate formal assessment of 
intraobserver and interobserver variability and whether 
or not there is evidence for a ‘learning curve’ effect.
Assessment of adverse events
Adverse events arising during the study will be recorded 
and managed in accordance with standard clinical 
practice.
Data management and monitoring
Data will be managed by a dedicated project manager 
to ensure validity, accuracy and reliability. Data will be 
handled in accordance with Good Clinical Practice and 
the Data Protection Act (2018). Participants will be 
assigned a study- specific ID. Written, informed consent 
will be obtained for all participants and forms stored in 
local site files within locked filing cabinets. Clinical data 
will be collected on case report forms (CRFs) and entries 
verified by inspection against source data. No patient 
identifiers will be stored in CRFs or on the study database. 
A sample of CRFs (10% or as per the study risk assess-
ment) will be checked on a regular basis for verification 
of all entries made. Deidentified data will be stored on a 
study- specific REDCap database. The capture of data on 
the study database will be checked and verified. Where 
corrections are required, these will carry a full audit trail 
and justification. The sponsor will periodically audit the 
study site file, a sample of CRFs, consent forms and source 
data and accuracy of the study database to ensure satisfac-
tory completion.
Statistical analyses
Statistical analyses will be carried out in R V.3.2.5 (R 
Development Core Team, Vienna, Austria) and overseen 
by the trial statistician. A STARD diagram depicting the 
flow of participants through the study will be presented. 
This will describe the number of participants who met 
the inclusion criteria but did not take part and reasons 
for this. Participants’ demographical and clinical charac-
teristics at baseline will be presented by final diagnosis 
using appropriate descriptive statistics, mean and SD for 
continuous measures that are approximately symmetrical 
median and quartiles if the distribution is skewed. Discrete 
outcomes will be described using both the number and 
proportion (percentage). The distribution of disease will 
also be presented for the index test by results of the refer-
ence standard.
Analysis of the primary objective will compare the 
clinical performance of cytology with the reference test. 
Thus, sensitivity, specificity, NPV, positive predictive 
value and diagnostic accuracy will be reported together 
with their corresponding 95% CIs, calculated using the 
exact binomial method. Where a histology result is not 
available, endometrial thickness <4 mm (histology not 
indicated) or discharge from diagnostic workup will be 
used as reference standard. Analysis of the secondary 
objectives will assess clinical performance of the urine 
test alone and the vaginal test alone for the detection of 
endometrial cancer in relation to the reference test. The 
clinical performance of urine and vaginal cytology for 
the detection of any cancer affecting the pelvic organs 
will also be calculated. Secondary analyses will follow the 
same approach as the primary analysis. Sensitivity analyses 
will consider the clinical performance of cytology with a 
broader definition of a positive cytology result (including 
glandular results as test positives). Interobserver agree-
ment between the cytopathologists will be assessed using 
the kappa statistic and categorised as poor, fair, moderate 
and good. McNemar’s χ2 test will be used to compare 
urogenital cytology with routine diagnostics. Multivariate 
logistic regression will evaluate the relationship between 
positive cytology and endometrial cancer diagnosis while 
adjusting for potentially predictive clinical characteristics 
like age and BMI. The diagnostic accuracy of urogenital 
cytology will be compared with individual elements of the 
standard diagnostic pathway, including TVS, hysteroscopy 
and endometrial biopsy. Consideration will be given as to 
where in the current diagnostic pathway for endometrial 
cancer urogenital cytology fits. Its use as a triage test prior 
to any other diagnostic workup both alone and in combi-
nation with clinical parameters (eg, age and BMI) will be 
modelled. We will also consider its usefulness in combi-
nation with transvaginal ultrasound scanning at various 
endometrial thickness cut- offs. The acceptability of 
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urogenital sampling will be compared with transvaginal 
ultrasound, hysteroscopy and endometrial biopsy (online 
supplemental appendix 1).
Planned secondary use of the data and samples
Beyond the scope of this diagnostic accuracy study, we 
will use the prospectively collected data to assess the clin-
ical performance of elements of the current diagnostic 
pathway, alone and in combination, including formal 
cost- effectiveness analyses, if resources permit. We will use 
the data to validate and compare the clinical performance 
of several published endometrial cancer risk prediction 
models and to develop a novel risk prediction model that 
includes urogenital cytology. We will report descriptive 
analyses of our cohort of women with PMB, including the 
distribution of risk factors and patterns of help- seeking 
behaviour. Residual urine and vaginal samples will be 
embedded in agar cell blocks or spun down and frozen 
for future translational research. Agar cell blocks will be 
used to identify cellular markers by immunohistochem-
istry that distinguish benign from malignant cells, for 
example, proliferation markers (Ki-67 and minichro-
mosome maintenance (MCM) 2, which may facilitate 
their identification using adjunct immunocytochemistry, 
single- cell platforms or flow cytometry. Frozen cell pellets 
and supernatant fractions will be used to search for novel 
genomic, metabolomic and proteomic biomarkers.
Ethics and dissemination
This study was adopted onto the National Institute for 
Health Research trial portfolio on 7 August 2018 and 
is sponsored by MFT. Any planned modifications to the 
protocol will be approved by the REC before they are 
adopted by the study. An audit trail of ethical amend-
ments and documentation will be kept to allow moni-
toring by the research team and external regulatory 
bodies (table 2). The study was registered with an Inter-
national Standard Randomised Controlled Trial Number 
on 9 August 2018.
Study management
The study management group comprises the principal 
investigator, project manager, cytology team, clinical 
research fellows, research nurses and statistician, who will 
jointly monitor study conduct and progress. All aspects of 
the study and all study personnel will adhere to the study 
protocol (version 4.4 or subsequent approved version) 
and Good Clinical Practice and Data Protection princi-
ples. Regular team meetings will ensure quick resolution 
of recruitment issues, study processes and data collection 
inconsistencies.
Patient and public involvement
The research question was developed in dialogue with 
patients, carers, members of the public and healthcare 
professionals. ‘Which women with abnormal bleeding 
require specialist referral for investigation?’ was ranked 
the second most important unanswered research ques-
tion in the James Lind Alliance Womb Cancer Priority 
Setting Partnership, recognising the need for better diag-
nostic pathways for endometrial cancer.19 ‘What simple, 
non- invasive, painless, cost- effective and convenient tests 
can be used to detect cancer early?’ was voted the most 
important research priority for detecting cancer early.8 
Urogenital cytology is simple, non- invasive and painless; 
whether it is effective for the detection of endometrial 
cancer is the focus of this study. We will disseminate our 
results through publication in peer- reviewed scientific 
journals; presentation at conferences; and via social 
media, blogs and charity websites.
DISCUSSION
The DETECT Study will establish the diagnostic test accu-
racy of vaginal and urine samples for endometrial cancer 
detection by cytology in women with PMB. Urogenital 
cytology could offer a simple, acceptable, easy to admin-
ister test that could be used in primary care as a triage 
tool for women with unexplained PMB. Cytology positive 
women could be referred for diagnostic workup, while 
cytology negative women are quickly reassured without 
the need for unpleasant, invasive, anxiety- provoking tests, 
with massive cost- saving implications for the NHS.
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